• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对《钆贝葡胺和钆塞酸二钠肝胆期在肝细胞腺瘤与局灶性结节性增生鉴别诊断中的患者内比较》的回复

Reply to "Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia".

作者信息

Reizine Edouard, Luciani Alain

机构信息

Department of Radiology, APHP, HU Henri Mondor, Creteil, France.

Faculté de Médecine, Universite Paris Est Creteil, Creteil, France.

出版信息

J Magn Reson Imaging. 2020 Oct;52(4):1279-1280. doi: 10.1002/jmri.27074. Epub 2020 Feb 5.

DOI:10.1002/jmri.27074
PMID:32022384
Abstract

LEVEL OF EVIDENCE

5 TECHNICAL EFFICACY STAGE: 3 CONFLICT OF INTEREST: None.

FINANCIAL SUPPORT

None. J. Magn. Reson. Imaging 2020;52:1279-1280.

摘要

证据级别

5 技术疗效阶段:3 利益冲突:无。

资金支持

无。《磁共振成像杂志》2020年;第52卷:1279 - 1280页。

相似文献

1
Reply to "Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia".对《钆贝葡胺和钆塞酸二钠肝胆期在肝细胞腺瘤与局灶性结节性增生鉴别诊断中的患者内比较》的回复
J Magn Reson Imaging. 2020 Oct;52(4):1279-1280. doi: 10.1002/jmri.27074. Epub 2020 Feb 5.
2
Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.患者内比较 Gd-BOPTA 和 Gd-EOB-DTPA 的肝胆期在肝细胞腺瘤与局灶性结节增生鉴别诊断中的作用。
J Magn Reson Imaging. 2019 Mar;49(3):700-710. doi: 10.1002/jmri.26227. Epub 2018 Sep 25.
3
Response to Letter: Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of HCA From FNH.对信件的回复:钆布醇与钆塞酸二钠肝胆期在肝细胞腺瘤与肝局灶性结节性增生鉴别诊断中的患者内比较
J Magn Reson Imaging. 2020 Oct;52(4):1281-1282. doi: 10.1002/jmri.27137. Epub 2020 Mar 23.
4
Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.良性肝细胞病变患者肝胆期摄取 Gd-BOPTA 与肿瘤分子特征的定量相关性。
Eur Radiol. 2018 Oct;28(10):4243-4253. doi: 10.1007/s00330-018-5438-7. Epub 2018 May 2.
5
[Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].[钆塞酸二钠增强磁共振成像:局灶性结节性增生与肝细胞腺瘤的鉴别诊断]
Acta Med Port. 2011 Dec;24 Suppl 2:531-8. Epub 2011 Dec 31.
6
Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?鉴别局灶性结节性增生与肝细胞腺瘤:使用线性钆螯合物的肝胆期 MRI(HBP-MRI)是否总是有用?
Abdom Radiol (NY). 2018 Jul;43(7):1670-1681. doi: 10.1007/s00261-017-1377-z.
7
HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.增强型肝细胞腺瘤及其在钆塞酸增强 MRI 中的与 FNH 鉴别
BMC Med Imaging. 2021 Feb 15;21(1):28. doi: 10.1186/s12880-021-00552-0.
8
Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules.钆塞酸二钠增强磁共振成像中的廓清表现:肝胆期呈反向摄取的肝细胞癌与局灶性结节样增生样结节之间的鉴别特征
J Magn Reson Imaging. 2017 Jun;45(6):1599-1608. doi: 10.1002/jmri.25493. Epub 2016 Oct 11.
9
Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.钆塞酸增强 MRI 肝胆期形态增强模式对鉴别局灶性结节增生与肝细胞腺瘤的诊断价值。
Radiol Med. 2021 Nov;126(11):1379-1387. doi: 10.1007/s11547-021-01403-2. Epub 2021 Jul 21.
10
Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.钆贝葡胺增强肝胆期磁共振成像定量分析在局灶性结节性增生与肝细胞腺瘤鉴别诊断中的作用
J Magn Reson Imaging. 2015 Nov;42(5):1249-58. doi: 10.1002/jmri.24897. Epub 2015 Apr 6.